[Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Rhea-AI Filing Summary

Teva Pharmaceutical Industries interim chief legal officer Brian Savage reported equity compensation activity involving restricted share units and ordinary shares. On March 5, 2026, 3,580 restricted share units were converted into 3,580 ordinary shares at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase. On the same date, he sold 1,127 ordinary shares at a weighted average price of $31.6684 per share, with the shares sold in multiple trades between $31.26 and $32.34. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of the restricted share units.

Insider Trade Summary

Net Seller: 1,127 shares ($35,690)

Net Sell 3 txns

Insider Savage Brian

Role Interim Chief Legal Officer

Sold 1,127 shs ($36K)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	3,580	$0.00	--
Exercise	Ordinary Shares	3,580	$0.00	--
Sale	Ordinary Shares	1,127	$31.6684	$36K

Holdings After Transaction: Restricted Share Units — 10,740 shares (Direct); Ordinary Shares — 12,041 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 5, 2025, with 3,580 vested on March 5, 2026, and 3,580 vesting on each of March 5, 2027, March 7, 2028 and March 5, 2029.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage Brian

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		3,580	A	(2)	12,041	D
Ordinary Shares(1)	03/05/2026		S		1,127(3)	D	$31.6684(4)	10,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			3,580	(5)	(5)	Ordinary Shares(1)	3,580	$0	10,740	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. Restricted share units were granted on March 5, 2025, with 3,580 vested on March 5, 2026, and 3,580 vesting on each of March 5, 2027, March 7, 2028 and March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TEVA interim CLO Brian Savage report?

Brian Savage reported RSU vesting and a related share sale. 3,580 restricted share units converted into ordinary shares, and 1,127 ordinary shares were sold in multiple trades to satisfy tax withholding obligations from the vesting event.

How many Teva (TEVA) shares did Brian Savage acquire through RSU vesting?

He acquired 3,580 ordinary shares through the conversion of restricted share units. Each unit represented a contingent right to receive one ordinary share or its cash value at settlement, reflecting equity compensation rather than an open-market purchase.

How many Teva (TEVA) shares did Brian Savage sell and at what price?

He sold 1,127 ordinary shares at a weighted average price of $31.6684. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, as disclosed in the weighted-average pricing footnote.

Why did Brian Savage sell Teva (TEVA) shares on March 5, 2026?

The sale of 1,127 Teva ordinary shares was made to cover tax withholding obligations. These obligations arose in connection with the vesting of restricted share units, according to the transaction footnote describing the purpose of the disposition.

What do Teva (TEVA) restricted share units represent for Brian Savage?

Each restricted share unit represents a contingent right to receive one ordinary share or the cash value of one ordinary share. Settlement occurs at vesting, reflecting equity compensation granted by Teva under its incentive arrangements.

Over what schedule do Brian Savage’s Teva (TEVA) RSUs vest?

Restricted share units were granted on March 5, 2025. According to the vesting schedule, 3,580 units vested on March 5, 2026, with an additional 3,580 scheduled to vest on each of March 5, 2027, March 7, 2028, and March 5, 2029.

How can Teva (TEVA) ordinary shares be held by investors and insiders?

Teva ordinary shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one ordinary share, allowing trading in U.S. markets while retaining underlying ordinary share ownership.